Financial

From Generative AI and ML to Quantum Computing, Bio-IT World 2025 Showcases Technologies Poised to Accelerate Lifesaving Therapies

Premier International Conference & Expo To Bring Together 3,000 Life Sciences and IT Leaders Focused on Advancing Precision Medicine BOSTON,...

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/...

Alternative Credentials Market for Higher Education to Grow by USD 1.84 Billion (2025-2029), Driven by Skills Gap and AI Redefining the Market Landscape – Technavio

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global alternative credentials market...

Quris-AI’s Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

Quris-AI to Provide Safety Assessments for Small Molecule Drug Candidates Before Initiating Clinical TrialsBOSTON and TEL-AVIV, Israel, Jan. 07, 2025...

CORRECTION: 2025’s Top-Rated EHR Vendors Across 40 Medical & Surgical Specialties: Black Book Insights Into Innovation and Client-Centric Excellence

Correction: This release has been updated to reflect accurate specialty-focused EHR top ratings. NextGen Healthcare has achieved five specialty-focused EHR...

U.S. Ambulatory EHR Market Report 2024-2031 – Integration of AI and ML Technologies to Offer Growth Opportunities for Market Players – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "U.S. Ambulatory EHR Market Size, Share, Forecast, & Trends Analysis by Deployment Mode, Type Application, Practice, End User...

SIPS Healthcare Solutions’ New Multimillion-Dollar Tech Acquisition Brings Affordable AI-Driven Innovation to Safety Net and Community Hospitals Nationwide

DALLAS, Jan. 6, 2025 /PRNewswire/ -- In a landmark move to revolutionize sterile processing and perioperative services, SIPS Healthcare Solutions...

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted...

error: Content is protected !!